Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 February 2018 Photo Johan Roux
Prof John Mubangizi appointed as UFS Dean of the Faculty of Law
Prof John Mubangizi.

The Council of the University of the Free State (UFS) approved the appointment of Prof John Mubangizi as Dean of the Faculty of Law during a meeting held on the Bloemfontein Campus on 22 January 2018. He assumed office on 1 February 2018.

“Prof Mubangizi’s extensive experience and scholarly contributions are most valuable to the university and the faculty, and I look forward to working with him,” says Prof Francis Petersen, Rector and Vice-Chancellor of the UFS.

Prof Mubangizi's academic qualifications include a Bachelor of Laws (LLB, Makerere University, Uganda), a Master’s in Public Law (LLM, University of Cape Town), and a Doctor of Laws (LLD, University of Durban-Westville). Prof Mubangizi also has several professional qualifications, including a Diploma in Education from Makerere University, and a Postgraduate Diploma in Legal Practice (Law Development Centre). He has been awarded several certificates in his area of academic specialisation, including a Certificate in Human Rights from the Institute of Human Rights (Strasbourg, France), and a Certificate in International Humanitarian Law from the Centre for Human Rights at the University of Pretoria.

He has been a full professor for more than twelve years. From January 2005 to April 2007, he served as Deputy Dean of the Faculty of Law at the University of KwaZulu-Natal (UKZN). From May 2007, he was Deputy Vice-Chancellor and Head of the College of Law and Management Studies at UKZN, with the responsibility of leading the academic and research strategy and realising the mandate of the college and the university.

One of the highlights of Prof Mubangizi’s research profile is the authorship of a book entitled The Protection of Human Rights in South Africa: A Legal and Practical Guide (2004 and 2013), which is widely used by scholars, practitioners, and students of human rights law in South Africa. He has published more than 60 publications, most of which are in SAPSE-accredited peer-reviewed journals. Furthermore, he has presented more than 40 academic papers at international conferences across the globe. He is rated by the National Research Foundation (NRF) as an established researcher.

Prof Mubangizi is a member of the Academy of Science of South Africa (ASSAf), and has served as member and advisor to the Council of ASSAf. He is currently the Chairperson of the Higher Education Quality Committee (HEQC) of South Africa, and a member of the Council on Higher Education (CHE). In addition, he serves on various committees and in different ad hoc positions at institutional, national, and international level.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept